research Fast clinical response with topical ruxolitinib in the management of non-segmental vitiligo detected by VISIA® analysis system
Topical ruxolitinib quickly improves non-segmental vitiligo.
Search
for
Sort by
Research
30-60 / 1000+ results
research Intoxication massive au lithium associée à une alopécie télogène diffuse
A woman survived a massive lithium overdose that caused a form of hair loss.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Tofacitinib for the treatment of lichen planopilaris: A case series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research Ion pairs of risedronate for transdermal delivery and enhanced permeation rate on hairless mouse skin
Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.
research Loose anchoring of anagen hairs and pili torti due to erlotinib
Erlotinib can cause hair loss and texture changes.
research Kinetic analysis of LY320236: competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5α-reductase
LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.
![The Synthesis of (−)-4-Methyl-8-Chloro-Trans-1,2,3,4,4a,5,6,10b-Octahydrobenzo-[f]-Quinolin-3-One-[3-14C] (LY300502-14C) via a Circuitous Route](/images/research/73bab8dc-bdf0-45e3-8ef7-73d0d4b93cb1/small/21074.jpg)
research The synthesis of (−)-4-methyl-8-chloro-trans-1,2,3,4,4a,5,6,10b-octahydrobenzo-[f]-quinolin-3-one-[3-14C] (LY300502-14C]) via a circuitous route
Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
research Efficacy and safety of tofacitinib in the treatment of adults with lichen planopilaris: A randomized placebo-controlled trial
research Potencial de nanopartículas poliméricas de Delonix contendo isotretinoína para o tratamento da acne
Delonix polymeric nanoparticles with isotretinoin effectively treat acne by targeting hair follicles and reducing skin irritation.
research Treatment of trichostasis spinulosa with 0.5-millisecond pulsed 755-nm alexandrite laser
The 755-nm alexandrite laser effectively and quickly treats trichostasis spinulosa with minimal pain and no side effects.
research A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib
A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.
research Hair Re-Pigmentation After Nilotinib
Nilotinib may cause gray hair to return to its original color.
research 491 Efficacy of oral tofacitinib in the treatment of lichen planopilaris
Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
research Inhibition of lipogenesis and sebum secretion for Lotus corniculatus seed extract in vitro and in vivo
Lotus corniculatus seed extract reduces oily skin by decreasing sebum production.
research Monilethrix: a typical case report with microscopic and dermatoscopic findings
A 6-year-old girl was diagnosed with a rare hair disorder and started treatment with topical minoxidil.
research [Studies on monilethrix].
Monilethrix is not caused by a metabolic defect.
research Antipsoriatic Activity of a New Synthetic Retinoid
The new synthetic retinoid RO 13-6298 effectively treated severe psoriasis at low doses with manageable side effects.
research A liposome-based formulation containing equol, dihomo-γ-linolenic acid and propionyl-l -carnitine to prevent and treat hair loss: A prospective investigation
The lotion with equol, dihomo-γ-linolenic acid, and propionyl-l-carnitine was effective in reducing hair loss in men and women.
research Oral Treatment of Keratinizing Disorders of Skin and Mucous Membranes With Etretinate
Etretinate was effective for certain skin conditions, but caused side effects like chapped lips, dry mucous membranes, and hair loss.
research Trichoscopic Markers and Clinical Response Patterns With Ritlecitinib in Severe Alopecia Areata: 24‐Week Outcomes From a Prospective Real‐World Cohort
Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.
research BH09 Mycophenolate mofetil in the management of lichen planus pigmentosus in a woman with frontal fibrosing alopecia
Mycophenolate mofetil effectively improved skin pigmentation and itching in a woman with lichen planus pigmentosus and frontal fibrosing alopecia.
research Calcipotriol/dithranol
research Kerion Celsi favored by the use of a tretinoin+minoxidil+betamethasone valerate lotion in a 28-year-old woman.
A lotion with tretinoin, minoxidil, and betamethasone valerate helped treat a woman's skin infection.
research Taurine‐based Active Pharmaceutical Ingredient Ionic Liquids Modulate the Perifollicular Microenvironment for Androgenic Alopecia Treatment
A new taurine-based liquid can help treat hair loss by improving hair follicle health and promoting regrowth.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.